Aspen Neuroscience completes Cohort 3 and 4 dosing in Parkinson's disease trial

Will Therapeutics announces CQDM-backed research collaboration to improve treatment for anorexia nervosa and other compulsive disorders

Biohaven completes enrolment in opakalim RISE 3 epilepsy study

ADC Therapeutics completes enrolment in Phase 1b ZYNLONTA combination trial

Sanofi reports positive phase 3 results for Nexviazyme in infantile-onset Pompe disease

Zelluna awarded NOK16m research grant for Phase 1 cancer study

AMR Clinical acquires ClinOhio Research Services

Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK

Viatris announces VR-205 Phase 3 Study results in Japanese adults with primary immunoglobulin A nephropathy

Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial

Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial

AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata

Neurogene reports durable positive long-term results from NGN-401 gene therapy in Rett syndrome trial

Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria

AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo